MedTrace Logo

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

NCT02057380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-11-20

No results posted yet for this study

Summary

The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.

Conditions

Interventions

DRUG

linsitinib

oral

DRUG

erlotinib

oral

DRUG

paclitaxel

Intravenous (IV) infusion

DRUG

Bortezomib

Subcutaneous or IV

DRUG

Dexamethasone

IV, Oral

Sponsors & Collaborators

  • Astellas Pharma Global Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Executive Medical Director · Astellas Pharma Global Development, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-16
Primary Completion
2016-10-14
Completion
2016-12-21

Countries

  • United States
  • Brazil
  • Czechia
  • Germany
  • Poland
  • Singapore
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057380 on ClinicalTrials.gov